The FTC is not anti-direct selling. It’s pro-truth in advertising.
The DSA misses the mark.
In May 2018, a class-action lawsuit was filed against two marketers of the diabetes medication Actos for allegedly misleadingly marketing the drug as safe and effective without disclosing the risks associated with taking the drug, including bladder cancer and congestive heart failure. (Fernandez et al v. Takeda Pharmaceuticals America, Inc. and Eli Lilly & Company, Case No. 18-cv-1142, E.D. Cal.)
The DSA misses the mark.
TINA.org reader takes issue with this product’s deceptive packaging.
Don’t let this company blindside you with its deceptive pricing.
Lawsuit pokes holes in company’s Swiss branding.
Why are these airport vendors slyly charging consumers for “employee benefits”?